Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03595150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Diclofenac for Prevention of Post-ERC Pancreatitis

StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2026 to Dec 31, 2027
    • Start date: Jan 1, 2025 to Jan 1, 2026
    • Study completion date: Dec 31, 2027 to Dec 31, 2028
    v9
  2. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Start date: Jan 1, 2024 to Jan 1, 2025
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v8
  3. Primary completion date: Dec 31, 2022 to Dec 31, 2025
    • Start date: Sep 1, 2022 to Jan 1, 2024
    • Study completion date: Mar 31, 2023 to Dec 31, 2026
    v7
  4. Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Start date: Sep 1, 2021 to Sep 1, 2022
    • Study completion date: Mar 31, 2022 to Mar 31, 2023
    v6
  5. Start date: Jan 1, 2021 to Sep 1, 2021v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Apr 1, 2020 to Jan 1, 2021v4
  2. Start date: Nov 1, 2019 to Apr 1, 2020v3
  3. Start date: Jan 1, 2019 to Nov 1, 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.
Trial Details
NCT Number NCT03595150
Lead Sponsor Karolinska Institutet
Collaborators: Uppsala University
Conditions
(from sponsor)		 Common Bile Duct Diseases
Related terms Common Bile Duct Diseases, Pancreatitis
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov